|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, January 31, 2019 ) Study estimates biosimulation market size for 2017 & projects its demand till 2022. In primary research process, various sources from both demand side & supply side were interviewed to obtain qualitative and quantitative information for report.
Download Free Brochure of Biosimulation Market Report With TOC Now at http://www.reportsnreports.com/contacts/requestsample.aspx?name=199952 .
Biosimulation market is projected to reach USD 2.88 Billion by 2022 from USD 1.38 Billion in 2017, at a CAGR of 15.9%. Factors like increase in R&D investments in pharmaceutical & biotechnology industries, growing adoption of biosimulation software by regulatory bodies, technologically advanced QSP systems, need to curtail drug discovery & development costs.
Target Audience for Biosimulation Market Report:
• Biosimulation product manufacturers, vendors, and distributors
• Market research and consulting companies
• Regulatory authorities
• Associations related to pharmaceutical and biotechnology research
• Biotechnology and pharmaceutical companies
• Academic and government research institutes
• Contract research organizations (CROs)
Click Now for More Details on Biosimulation Market Report with Top Trends, Forecast, Analysis and Overview at https://www.openpr.com/news/1514619/Biosimulation-Industry-2022-Market-Research-Report-Projected-to-Reach-US-2-88-Billion-by-2022-from-USD-1-38-Billion-at-a-CAGR-of-15-9-Top-Players-Key-Insights-Overview-Company-Profiles-Shares-Geographical-Forecast.html .
North America is expected to account for the largest share of the market followed by Europe. However, Europe is expected to register the highest CAGR during the forecast period. The growing focus on research-related funding activities by governments is expected to assist in the development of drug discovery and development process, thus driving the demand for biosimulation in European region.
Market Overview
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 Increase in R&D Investments in the Pharmaceutical and Biotechnology Industries
5.2.1.2 Growing Adoption of Biosimulation Software By Regulatory Bodies
5.2.1.3 Technologically Advanced Qsp Systems
5.2.1.4 Need to Curtail Drug Discovery and Development Costs
5.2.1.5 Growth in the Biologics and Biosimilars Markets
5.2.2 Restraint
5.2.2.1 Lack of Standardization
5.2.3 Opportunities
5.2.3.1 Emerging Applications
5.2.3.2 Increased Use of Personalized Medicine
5.2.3.3 Use of Biosimulation Solution for Pediatric Drug Development
5.2.4 Challenges
5.2.4.1 Difficulty in Matching the Complexity of Biological Systems and Processes
5.2.4.2 Shortage of Biosimulation and Modeling Experts
#More Information on “Biosimulation Market by Product (Software, Molecular Simulation, In House, Contract Services), Application (Clinical Trials, PKPD, ADME), Delivery (Subscription, Ownership), End User (Biotech, Pharma Companies, CROs, Regulatory) - Global Forecast to 2022” research report can be requested at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=199952 .
Top players in biosimulation market operating are Certara (US), Simulation Plus (US), Dassault Systčmes (France), Schrödinger (US), ACD/Labs (Canada), Chemical Computing Group (Canada), Physiomics (UK), Evidera (US), In silico biosciences (US), INOSIM Software (Germany), Insilico Biotechnology (Germany), LeadInvent Technologies (India), Rosa (US), Nuventra Pharma (US), and Genedata (Switzerland).
Premium Insights
1 Biosimulation Market Overview
2 Biosimulation Software Market, By Type
3 Geographic Analysis: Biosimulation Market in Europe, By End User and Country
4 Biosimulation Drug Developement Market, By Type
ReportsnReports
Snehal
+ 18883915441
sales@reportsandreports.com
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
